Legal & General Group Plc Has $15.86 Million Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Legal & General Group Plc reduced its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 12.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 128,774 shares of the specialty pharmaceutical company's stock after selling 17,694 shares during the quarter. Legal & General Group Plc owned 0.21% of Jazz Pharmaceuticals worth $15,859,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in JAZZ. Pacer Advisors Inc. raised its stake in shares of Jazz Pharmaceuticals by 5.5% during the fourth quarter. Pacer Advisors Inc. now owns 2,214,480 shares of the specialty pharmaceutical company's stock valued at $272,713,000 after purchasing an additional 115,102 shares in the last quarter. JPMorgan Chase & Co. raised its position in shares of Jazz Pharmaceuticals by 4.8% during the 4th quarter. JPMorgan Chase & Co. now owns 1,587,541 shares of the specialty pharmaceutical company's stock worth $195,506,000 after buying an additional 72,007 shares in the last quarter. Franklin Resources Inc. lifted its stake in shares of Jazz Pharmaceuticals by 4.6% in the 3rd quarter. Franklin Resources Inc. now owns 1,118,688 shares of the specialty pharmaceutical company's stock worth $124,208,000 after acquiring an additional 48,708 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in shares of Jazz Pharmaceuticals by 15.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 615,517 shares of the specialty pharmaceutical company's stock valued at $75,801,000 after acquiring an additional 83,807 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its stake in shares of Jazz Pharmaceuticals by 5.4% during the fourth quarter. Bank of New York Mellon Corp now owns 477,751 shares of the specialty pharmaceutical company's stock valued at $58,835,000 after acquiring an additional 24,481 shares during the period. Institutional investors own 89.14% of the company's stock.

Jazz Pharmaceuticals Trading Up 1.2 %

Shares of Jazz Pharmaceuticals stock traded up $1.23 during trading on Friday, reaching $102.78. 995,175 shares of the company were exchanged, compared to its average volume of 789,371. Jazz Pharmaceuticals plc has a twelve month low of $95.49 and a twelve month high of $148.06. The business has a 50-day moving average price of $127.60 and a 200-day moving average price of $122.32. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The firm has a market capitalization of $6.24 billion, a price-to-earnings ratio of 14.48, a P/E/G ratio of 1.04 and a beta of 0.42.

Insider Activity

In related news, CMO Robert Iannone sold 2,403 shares of the company's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $138.41, for a total value of $332,599.23. Following the completion of the sale, the chief marketing officer now owns 79,621 shares in the company, valued at $11,020,342.61. This represents a 2.93 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Bruce C. Cozadd sold 1,500 shares of the business's stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $122.31, for a total value of $183,465.00. Following the completion of the transaction, the chief executive officer now directly owns 439,744 shares of the company's stock, valued at approximately $53,785,088.64. The trade was a 0.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 28,736 shares of company stock valued at $4,023,305 in the last ninety days. 4.20% of the stock is owned by insiders.

Analysts Set New Price Targets

JAZZ has been the subject of a number of research reports. Piper Sandler reaffirmed an "overweight" rating and set a $176.00 price target (up from $163.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, February 26th. UBS Group raised Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and lifted their target price for the stock from $145.00 to $179.00 in a report on Friday, March 7th. Truist Financial upped their price target on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a "buy" rating in a report on Thursday, March 6th. Morgan Stanley reaffirmed an "overweight" rating and issued a $183.00 price objective (up previously from $175.00) on shares of Jazz Pharmaceuticals in a research note on Friday, March 7th. Finally, Cantor Fitzgerald lowered shares of Jazz Pharmaceuticals from an "overweight" rating to a "neutral" rating and increased their target price for the company from $140.00 to $150.00 in a research note on Wednesday, February 26th. One research analyst has rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of "Buy" and an average target price of $187.71.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.